Page 2 - Arcus Bioscience News Today

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the...

Wedbush reiterated their outperform rating on shares of Arcus Biosciences (NYSE:RCUS – Free Report) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The brokerage currently has a $30.00 target price on the stock. Wedbush also issued estimates for Arcus Biosciences’ FY2028 earnings at $1.87 EPS. A number of other research analysts […]

Wedbush reiterated their outperform rating on shares of Arcus Biosciences (NYSE:RCUS – Free Report) in a research note released on Thursday, MarketBeat reports. Wedbush currently has a $30.00 price objective on the stock. Wedbush also issued estimates for Arcus Biosciences’ FY2028 earnings at $1.87 EPS. Other equities analysts have also recently issued research reports about […]

Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical...

HAYWARD, Calif.--(BUSINESS WIRE)--Feb 21, 2024--

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the...

Arcus Biosciences , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management...

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated ...

– Investment Reinforces Companies’ Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Program – – Additional Equity Investment of $320M, Raising Gilead’s...

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the...